Patricia Inácio, PhD, science writer —

The International Myeloma Foundation (IMF) is one of the nonprofit organizations awarded the 2022 Amazon Web Services (AWS) IMAGINE Grant, which was established to help harness technology for patients’ needs. IMF was a winner in the Momentum to Modernize category, wherein its efforts to use cloud technology to educate…

The U.S. Food and Drug Administration (FDA) will review BioLineRx’s application to approve Aphexda, formerly known as motixafortide, as an add-on stem cell mobilization therapy to improve stem cell transplants in people with multiple myeloma. The decision comes about two months after the company submitted a…

Janssen’s Tecvayli (teclistamab) has been approved for certain adults with relapsed or refractory multiple myeloma in the U.S., but access is limited due to potential side effects. In particular, the approval by the U.S. Food and Drug Administration (FDA) is for patients who have received at least four…

Note: This story was updated Sept. 26, 2022, to correct the fact that Abecma is approved for patients in Europe and Japan who have undergone at least three prior therapies, not four as originally stated.  The CAR T-cell therapy Abecma (idecabtagene vicleucel) significantly extended survival without signs of disease worsening…

STAR-LLD, an investigational continuous delivery of low doses of lenalidomide into the blood — being developed as a new treatment option for multiple myeloma — was well-tolerated in healthy volunteers in a Phase 1 clinical trial, with no dose-related toxicity or adverse events, data show. Moreover, the treatment…

Xpovio (selinexor) combined with Kyprolis (carfilzomib) and low-dose dexamethasone leads to strong and durable responses in heavily pretreated multiple myeloma patients, results from a Phase 1/2b trial show. The study, “Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients,” was published…

Janssen has submitted an application to regulators in Japan seeking the approval of ciltacabtagene autoleucel, an investigational CAR T-cell therapy also known as cilta-cel, to treat relapsed or refractory multiple myeloma patients. The submission to the Japanese Ministry of Health, Labour and Welfare (MHLW) specifically asks that…

People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program. This program, also known as a named patient program, allows patients and doctors in countries where a medicine is not yet approved or…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies for rare and serious diseases by granting them various financial and regulatory benefits. These include exemptions from…

The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment of people with multiple myeloma who received at least one line of therapy. The approval, which comes three months ahead of deadline, was based…